These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 2333829)

  • 1. Guidelines for using superpotent topical steroids.
    Prawer SE; Katz HI
    Am Fam Physician; 1990 May; 41(5):1531-8. PubMed ID: 2333829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible side effects of topical steroids.
    Morman MR
    Am Fam Physician; 1981 Feb; 23(2):171-4. PubMed ID: 6450525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids.
    Walsh P; Aeling JL; Huff L; Weston WL
    J Am Acad Dermatol; 1993 Sep; 29(3):501-3. PubMed ID: 8349876
    [No Abstract]   [Full Text] [Related]  

  • 4. The use and abuse of 0.05 per cent clobetasol propionate in dermatology.
    Harris DW; Hunter JA
    Dermatol Clin; 1988 Oct; 6(4):643-7. PubMed ID: 3229014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clobetasol--a potent new topical corticosteroid.
    Med Lett Drugs Ther; 1986 Jun; 28(715):57-9. PubMed ID: 3520267
    [No Abstract]   [Full Text] [Related]  

  • 6. Topical clobetasol-17-propionate: review of its clinical efficacy and safety.
    Olsen EA; Cornell RC
    J Am Acad Dermatol; 1986 Aug; 15(2 Pt 1):246-55. PubMed ID: 3528243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic-pituitary-adrenal function in children with atopic dermatitis treated with clobetasone butyrate and its clinical evaluation.
    Boner AL; Richelli C; De Stefano G; Valletta EA; Ferrari S; Mengoni M
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):118-20. PubMed ID: 2985514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clobetasol propionate and betamethasone-17,21-dipropionate with reference to adrenal suppression.
    Eriksen K
    Acta Derm Venereol; 1979; 59(4):372-4. PubMed ID: 92159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.
    Katz HI; Hien NT; Prawer SE; Mastbaum LI; Mooney JJ; Samson CR
    J Am Acad Dermatol; 1987 Apr; 16(4):804-11. PubMed ID: 3553247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
    Andres P; Poncet M; Farzaneh S; Soto P
    J Drugs Dermatol; 2006 Apr; 5(4):328-32. PubMed ID: 16673799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Emovate in pediatric practice. A Swiss study on a new local corticosteroid].
    Graber W; Miescher A; Schneider HJ
    Ther Umsch; 1983 May; 40(5):449-53. PubMed ID: 6346567
    [No Abstract]   [Full Text] [Related]  

  • 13. Topical application of calcipotriene and corticosteroids: combination regimens.
    Lebwohl M
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 2):S55-8. PubMed ID: 9344186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations.
    Gilbertson EO; Spellman MC; Piacquadio DJ; Mulford MI
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 2):318-21. PubMed ID: 9486706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clobetasone butyrate, a topical steroid in geriatrics].
    Bonavita E; Bassi R; Mengoni M
    Clin Ter; 1985 Mar; 112(5):423-8. PubMed ID: 4017467
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
    Katz HI; Lindholm JS; Weiss JS; Shavin JS; Morman M; Bressinck R; Cornell R; Pariser DM; Pariser RJ; Weng W
    Clin Ther; 1995; 17(3):390-401. PubMed ID: 7585843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peristomal dermatoses: a novel indication for topical steroid lotions.
    Lyon CC; Smith AJ; Griffiths CE; Beck MH
    J Am Acad Dermatol; 2000 Oct; 43(4):679-82. PubMed ID: 11004626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPA-suppressive effects of aqueous clobetasol propionate in the treatment of patients with oral lichen planus.
    Gonzalez-Moles MA; Scully C
    J Eur Acad Dermatol Venereol; 2010 Sep; 24(9):1055-9. PubMed ID: 20158585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical steroids: a guide for use in the elderly patient.
    Pariser DM
    Geriatrics; 1991 Oct; 46(10):51-4, 57-60, 63. PubMed ID: 1916302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
    Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
    Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.